Background: To identify novel proteins involved in multidrug resistance in chronic myeloid leukemia (CML). Materials and methods: Comparative proteomics was used to screen multidrug resistance-related proteins from K562 and K562/A02; the differently expressed proteins were further confirmed by western blot and real-time PCR. short hairpin RNA (shRNA) assay was applied to determine the relationship between candidate protein and adriamycin resistance. Bisulfite sequencing was carried out to assess methylation status of candidate multidrug resistance-related gene promoter. K562/A02 was treated with 5-azacytidine or trichostatin A (TSA); multidrug resistance phenotype and corresponding protein or gene changes were detected.
introduction
Adriamycin and its analogues daunomycin and mitoxantrone are widely used for treatment of hematologic malignancies, especially acute myeloid leukemia and chronic myeloid leukemia (CML) with blast crisis (BC). However, it is common for such patients to develop resistance to adriamycin. Although substantial improvement in patient survival may be obtained with the use of imatinib in some CML with BC cases, curative effect from imatinib is only minimal. It is mainly caused by the development of chemotherapy resistance, particularly multidrug resistance [1] .
Various assumptions have been proposed to explain multidrug resistance. Some indicate that the mechanisms may involve P-glycoprotein (P-gp) [2] , glutathione-s-transferase (GST) [3] and sorcin, which is a soluble resistance-related calcium-binding protein [4] . Obviously, elucidating the mechanisms at the molecular level is of great importance to the design of counter-resistance strategies.
Recently, down-regulation of mitochondrial ATPase expression has been reported in several solid tumors such as carcinomas of the liver, kidney, colon, esophagus, lung, breast and stomach [5] [6] [7] [8] . These results not only provide compelling evidence that bioenergetic dysfunction of mitochondria is a hallmark of these types of tumors but also show that altered mitochondrial ATPase expression is attributed to 5-fluorouracil resistance in human colon cancer cells.
In searching for novel mechanisms involved in multidrug resistance and exploring the possible role of mitochondrial ATPase in the development of adriamycin resistance in leukemia, we carried out comparative proteomics and analyzed the differences in global protein expression in leukemia cell line K562 and its multidrug resistance counterpart, K562/A02 [9] . Our results indicate that mitochondrial ATPase down-regulation indeed plays an important role in adriamycin resistance in leukemia cells, possibly through DNA methylation regulation.
materials and methods cell line and primary samples
Adriamycin-resistant CML cell line K562/A02 was provided by the Institute of Hematology, Tianjin, China, and K562 was from our laboratory. K562/A02 and K562 were maintained in RPMI-1640 (Gibco-BRL, Grand Island, NY) with 10% fetal bovine serum (Gibco-BRL) in the presence and absence of 1 lg/ml adriamycin at 37°C in a humidified 5% CO 2 atmosphere. Bone marrow samples were collected from 32 CML patients (10 for western blot and realtime PCR; 22 for methylation identification). Bone marrow mononuclear cells were isolated by Ficoll density gradient centrifugation. Confirmation of CML diagnosis was based on cell morphology and cytogenetic assays. All patients were positive on Philadelphia chromosome. In 22 patients for methylation assay, there were 9 in chronic phase (CP), 6 in accelerated phase (AP) and 7 in BC. The study was approved by our institutional review board and written informed consent was obtained from all patients.
flow cytometry analysis P-gp expression on K562/A02 and K562 was evaluated using polyethyleneconjugated anti-P-gp antibody (BD Biosciences, San Jose, CA). Cell cycle progression was detected with BD FACScan flow cytometer (BD Biosciences) and analyzed with Cell Quest software (BD Biosciences).
two-dimensional gel electrophoresis-based comparative proteomics
Two-dimensional gel electrophoresis (2-DE) was carried out as previously described [10] . Briefly, 1 mg protein of K562/A02 or K562 was applied to 24-cm immobilized pH gradient strip (pH3-10L) (Amersham Biosciences, Uppsala, Sweden). The second-dimension separation used sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Blue silver staining was used to visualize the protein spots in gels [11] . PDQuest system (Bio-Rad Laboratories, Hercules, CA) was used for image analysis. Proteins with altered abundances of more than twofold were subjected to matrixassociated laser desorption ionization-mass spectroscopy analysis for identification [10] . Briefly, protein spots were excised and gel pieces were incubated in 10-ll digestion solution with 20 lg/ml trypsin (Promega, Madison, WI) for 10-12 h at 37°C. The tryptic peptide mixture was mixed with a-cyano-4-hydroxycinnamic acid matrix solution (Sigma-Aldrich, St Louis, MO). One microliter of the mixture was analyzed by Voyager System DE-STR 4307 matrix-assisted laser desorption/ionization time of flight mass spectrometer (Applied Biosystems, Foster City, CA). Database searches with monoisotopic peptide masses were carried out against the SwissProt or NCBInr database with Mascot search engine.
RNA isolation and real-time PCR
Total RNA was isolated from 5 · 10 6 cells using Trizol (Gibco-BRL) following manufacturer's protocol. Five micrograms of RNA was reverse transcribed into complementary DNA using A3500 Reverse Transcription System (Promega). Real-time PCR was carried out on Roche LightCycler system (Roche Diagnostics, Mannheim, Germany) using DyNAmoä SYBRÒ Green qPCR Kit (FINNZYMES, Espoo, Finland). Primer for mitochondrial ATPase b subunit was as follows: sense, 5#-TGGTGGTGCTGGACTTGG-3#; antisense, 5#-GCCTGGGTGAAGCGAAAG-3#. Primers for glyceraldehyde-3-phosphate dehydrogenase, GST and Bcr-abl were synthesized as previously described [10, 12, 13] .
western blot
For protein extraction, cells were homogenized on ice in lysis buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM phenylmethansulfonylfluorid; 0.1 % sodium dodecyl sulfate; 1% Nonidet P-40; 5 lg/ml aprotinin) and cellular debris was pelleted at 10 000 g for 10 min at 4°C.
Protein was quantified using Bradford method and separated by 10% SDS-PAGE, then transferred on to polyvinylidene fluoride membranes (Amersham Biosciences) and probed with antibodies against GST (Chemicon, Victoria, Australia) and mitochondrial ATPase b subunit (Abcam, Cambridge, UK).
shRNA assay
The following sequence was applied to generate shRNAs: 5#-CCAGTTTGATGAGGGACTA-3# (nucleotides 324-342 of GenBank accession No: NM_001686) for mitochondrial ATPase b subunit translation initiation site. The forward sequences of shRNAs (5#-CCAGTTTGATGAGGGACTA-3#) and the reverse sequences (5#-GGUCAAACUACUCCCUGAU-3#) were connected by a nine-nucleotide hairpin loop (UUCAAGACG) and a poly(T) termination signal in pGenesil-1 plasmid vector (Genesil Biotechnology, Wuhan, China). The scrambled sequences [control short hairpin RNA (shRNA)], composed of same nucleotides as in shRNA but in randomized order, were used as negative control. The shRNA duplexes were transfected into K562 via electroporation as previously described [8] . The effects of shRNA on mitochondrial ATPase expression were determined by western blot at 48 h after transfection. The chemosensitivity of transfected K562 to adriamycin was evaluated by methylthiazoltetrazolium (MTT) assay [14] .
apoptosis analysis K562 cells transfected by shRNA were treated with 0.5mg/l adriamycin for 48 h. The apoptotic morphology of K562 was evaluated by Hoechst 33258 (Genesil Biotechnology) [15] . Early apoptosis was evaluated using Annexin V-FITC Apoptosis Detection Kit (BD Biosciences) following manufacturer's protocol.
bisulfite sequencing
Five micrograms of purified DNA from K562/A02, K562 or primary CML cells was treated with sodium bisulfite (Sigma-Aldrich), which only converted unmethylated cytosine to uracil, and then the desired sequence [217 bp (2278 to 262) mitochondrial ATPase b subunit promoter] was amplified using nested PCR [16] . Primers were designed according to MethPrimer (http://www.urogene.org/methprimer/). The following primers were used-round I: sense, 5#-ACCCAATAAACCTACCTACTACAAC-3#; antisense, 5#-AGATAGGGTAAAATATATTTTAGGAAAT-3# and round II: sense, 5#-TTGTTTTTAGTTTAGTTTTTATTGC-3#; antisense, 5#-TCCTATAAATGTCCCATTCTTATTCTC-3#. The PCR product containing 13 potential methylatable CG pairs was cloned into pGEM-T Vector System (Tiangen Biotech, Beijing, China) and five independent clones for each PCR product were sequenced by Biosune Inc. (Shanghai, China). We also carried out bisulfite sequencing on the samples of before and after 5-azacytidine (5-Aza) treatment from K562/A02, three CML-AP patients' or three CML-BC patients' primary cells. was also treated with low-dose 5-Aza (10 lM) and TSA (200 nM) in combination. After 48 h, total RNA and protein were extracted. Primer for mitochondrial ATPase b subunit (326 bp) was as follows: sense, 5#-GTGCCTGCTGATGACTTG-3#; antisense, 5#-TCCTGGAGGGATTTGTAG-3#. b-actin was designated as control [17] . PCR products were visualized by ethidium bromide after electrophoresis on a 1.5% agarose gel. Mitochondrial ATPase b subunit protein was determined by western blot. results
up-regulation of P-gp on K562/A02
Flow cytometry results showed that P-gp-positive cells in K562/ A02 were 20.45%, which was 10-fold higher than that of K562 (2.32%), confirming the multidrug resistance character of K562/A02. Cell cycle analysis showed that K562/A02 and K562 were almost in the same cell cycle progression. These results ensure the comparability of these two cell lines with regard to the following proteomics approaches.
altered protein profiles in K562/A02 and K562
In the pH range 3-10, 2-DE of K562/A02 and K562 displayed 1000 spots each. We found 17 protein spots of different density between K562/A02 and K562 ( Figure 1 inhibition of mitochondrial ATPase b subunit leads to decreased chemosensitivity and increased apoptotic resistance by shRNA on K562
To uncover a causative relationship of mitochondrial ATPase for adriamycin resistance, K562 were transfected with shRNA specific to mitochondrial ATPase b subunit. The expression of mitochondrial ATPase b subunit was significantly downregulated on K562 transfected with shRNA ( Figure 3A) . MTT assay showed that shRNA transfection led to decreased adriamycin sensitivity and the concentration that causes 50% inhibition of growth (IC 50 ) was 0.114 mg/l, compared with that of 0.038 mg/l in control shRNA, representing a threefold decrease toward drug sensitivity ( Figure 3B ). Effects of apoptotic resistance to adriamycin were observed by Hoechst 33258 and Annexin V assay. The Hoechst 33258 assay showed that the percentage of apoptosis on K562 of transfected shRNA was 16.8%, which was significantly lower than that on K562 of transfected control shRNA (29.5%) and phosphate-buffered saline (PBS) buffer only (26.7%). The result of Annexin V assay was consistent with Hochest 33258, in which the percentage of apoptosis on K562 of transfected shRNA (12.4%) was lower than that on K562 of transfected control shRNA (30.5%) and PBS buffer only (32.7%) ( Figure  3C ). These findings indicate that mitochondrial ATPase plays an important role in regulating K562 apoptosis and is involved in the adriamycin resistance of K562/A02.
We also analyzed the expressions of Bcr-Abl transcripts before and after K562 transfection. The results showed that shRNA had no influence on Bcr-Abl levels, indicating that chemoresistance mediated by mitochondrial ATPase may be independent of Bcr-Abl signal pathway.
mitochondrial ATPase b subunit methylation status on cell line and CML primary cells Through bisulfite sequencing, we found 26 (18.18%) and 0 (0%) of totally analyzed 143 CG pairs to be methylated in K562/A02 and K562, respectively (P = 0.003); the analyzed sequence and methylation status of each CG pair was showed in Figure 4A and B. K562/A02 displayed a higher methylation status on mitochondrial ATPase b subunit compared with K562.
We also analyzed the methylation sequence in primary cells from 22 CML patients. The results showed that 121 (26.59%) of analyzed 455 CG pairs for CML-BC and 31 (7.95%) of analyzed 390 CG pairs for CML-AP were methylated (P = 0.009), and the average methylation frequency of each CG pair is showed in Figure 4C and D. More interestingly, we did not detect any methylated CG pair in 585 CG pairs for CML-CP.
hypermethylation status of mitochondrial ATPase b subunit promoter is related to adriamycin resistance Mitochondrial ATPase b subunit transcription or translation levels were significantly increased in 5-Aza-treated K562/A02 both in mRNA abundance and protein level ( Figure 5A) ; on K562/A02, it was also up-regulated slightly by TSA ( Figure 5B ). While K562/A02 cells were exposed simultaneously to 5-Aza and TSA, a synergic effect was observed. Compared with treatment with either agent alone, relatively low concentration of 5-Aza combined with TSA led to increased expressions of both mRNA and protein of mitochondrial ATPase b subunit on K562/A02 ( Figure 5C ).
We then carried out chemosensitivity assay to determine the contribution of hypermethylation of mitochondrial ATPase to adriamycin resistance. MTT assay demonstrated that 5-Aza treatment led to increased adriamycin sensitivity on K562/A02: the IC 50 of K562/A02 (10 lM 5-Aza) was 0.394 mg/l, compared with untreated K562/A02 (IC 50 was 4.16 mg/l); chemosensitivity increased by 10-fold ( Figure 5D ).
We also analyzed the effect of 5-Aza on mitochondrial ATPase gene methylation. K562/A02 and primary cells from three CML-BC and three CML-AP patients were treated separately with 10 lM 5-Aza for 48 h and bisulfite sequencing analysis was carried out. Compared with untreated cells, 5-Aza had significant effect on the methylation status of mitochondrial ATPase. Before 5-Aza treatment, the methylated frequencies of K562/A02, CML-BC and CML-AP were 18.18%, 21.54% and 9.62%, respectively, which all decreased to 0% after 5-Aza treatment. as P-gp [2] . Actually, blasts of CML-BC exhibit a high expression of P-gp, whereas little expression is found during CML-CP [18] . While various P-gp inhibitors are applied, only limited clinical benefits are achieved [19] , indicating that P-gp is not the major or only mechanism of chemoresistance. Therefore, the development of effective multidrug resistance reversal agents is becoming urgent and depends greatly on our understanding to multiple molecular events involved in the generation of multidrug resistance. By proteomics approaches, we detected 17 differentially expressed proteins; 4 of which were overexpressed and 13 were down-regulated in K562/A02. These proteins might be classified into four groups in the functional sense: (i) growthassociated proteins; (ii) metabolic enzymes; (iii) cytokinerelated proteins and (iv) signal transduction-associated proteins. Among these proteins, a few have been proven to be related to chemoresistance, such as GST and mitochondrial ATPase b subunit. Looking at the protein expression profile, we found that mitochondrial ATPase b subunit, which is known to have an important role in bioenergic metabolism and development of chemoresistance of cancer cells [20, 21] , displays lower expression in K562/A02, and the phenomenon was further confirmed by western blot and quantitative PCR.
Mitochondria play an important role in energy metabolism and apoptosis [22, 23] . Over 70 years ago, Warburg [24, 25] observed that cancer cells frequently exhibit increased glycolysis, attributing this metabolic alteration to mitochondrial 'respiration injury' and considering it the origin of cancer cells. Recently, Cuezva et al. [5, 26] found a reduction in mitochondrial activity in liver cancer cells and lower expression of mitochondrial ATPase in kidney, colon, lung, breast and gastric cancers [5] [6] [7] , indicating that mitochondrial To further document the relationship between mitochondrial ATPase and adriamycin resistance, shRNA approach was applied on K562-the parental cell line of K562/A02. shRNA transfection was able to suppress mitochondrial ATPase expression and decrease sensitivity to adriamycin. This observation strongly supports the fact that down-regulation of mitochondrial ATPase may be a single molecular event to regulate the response to adriamycin in human leukemia cells. Accordingly, K562 transfected with shRNA exhibited an obviously apoptotic-resistance effect to adriamycin. While a direct correlation between mitochondrial ATPase defection and impairment of apoptosis pathway cannot be clearly established in our experiments, there have been literature indicating that acquired chemoresistance in cancer cells could involve increased BCL-2 and BCL-XL expressions or XIAP overexpression [27, 28] , indicating an interconnection for chemoresistance and antiapoptotic effect. Because the oxidative phosphorylation capability of cancer cells is diminished, the apoptotic potential of the cells, including mitochondrialmediated apoptosis, is hampered [20, 21] . These data probably provide an explanation for down-regulated mitochondrial ATPase and apoptotic resistance in K562/A02. However, the exact mechanisms remain to be elucidated in future studies.
It has been recognized that epigenetic factors occur in tumor formation, progression and chemoresistance [29] . SeguraPacheco et al. [30] described a global DNA hypermethylationrelated adriamycin resistance in MCF-7 cells and found that the multidrug resistance phenotype of MCF-7/Adr cells was accompanied by global DNA hypermethylation, whereas hydralazine, a specific demethylating agent, was applied, the resistant phenotype can be reverted. Our data showed that K562/A02 cells displayed hypermethylation status on mitochondrial ATPase b subunit promoter. When hypermethylation was inhibited by 5-Aza, it not only upregulated the expression of mitochondrial ATPase but also enhanced the adriamycin sensitivity of K562/A02, indicating that the epigenetic regulation on mitochondrial ATPase may reverse the resistant phenotype of K562/A02. We also observed that TSA could slightly up-regulate mitochondrial ATPase level, and no evident effect was found for adriamycin resistance reversal; combined interference of 5-Aza and TSA has a synergistic effect on K562/A02. These findings indicate that preclinical treatment strategies combining DNA methylation inhibitor and HDAC inhibitor should be evaluated to reduce the potential development of adriamycin resistance in CML patients.
Furthermore, we investigated the methylation status of mitochondrial ATPase on primary cells from 22 CML patients. Noticeably, among CML patients of different stages, there were significant differences in the frequencies of methylated cytosine. The changes were basically correlated with the status of chemoresistance in CML patients of various stages with hypermethylation. Our results reflect that hypermethylation of mitochondrial ATPase gene existed in the primary CML cells with chemoresistance, which was responsible for the drugresistant phenotype of CML-AP or CML-BC. These observations would prove to be pertinent and useful in the development of counter-chemoresistance strategies.
In summary, our study illustrates that down-regulation of mitochondrial ATPase occurs in CML cells with induced adriamycin resistance, and DNA hypermethylation of mitochondrial ATPase promoter may be responsible for the 
